Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of BMS-986231 infusion on diuretic response in HFrEF
2018-000970-31Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: 4-hour urinary output after IV furosemide. Started Jun 2018; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2018-000970-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000970-31.